drugset / Trial / NCT03693131

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

NCT03693131

Phase 3 Completed 580 enrolled Mochida Pharmaceutical Company, Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.

Timeline

Start
2018-10-27
Primary completion
2019-06-15
Completion
2019-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Eicosapentaenoic acid Small molecule 0.9 g Oral
Subject Eicosapentaenoic acid Small molecule 2 g Oral
Subject Eicosapentaenoic acid Small molecule 4 g Oral

Indications